BioCentury
ARTICLE | Clinical News

Orteronel: Development discontinued

June 30, 2014 7:00 AM UTC

Takeda discontinued development of orteronel for prostate cancer after reporting mixed Phase III data in metastatic CRPC. Takeda said orteronel did not demonstrate a clinical profile “sufficient” to m...